ELAN Revenue Flow
Filed revenue amounts for 2026-04-01 to 2026-06-30. Coverage is partial. Unconnected amounts are separate disclosures; they must not be added together.
- 2026-06-30: Revenue $1.37B; Revenue including tax (m); Cost of revenue $570.00M; Research and development $92.00M.
- 2026-03-31: Revenue $1.37B; Revenue including tax (m); Cost of revenue $586.00M; Research and development $97.00M.
- 2025-12-31: Revenue $1.14B*; Revenue including tax (m); Cost of revenue $555.00M*; Research and development $93.00M*.
- 2025-09-30: Revenue $1.14B; Revenue including tax (m); Cost of revenue $530.00M; Research and development $89.00M.
Product or service
Separate filed amounts; connecting flows are not established. Components and totals may overlap.
Geography
Separate filed amounts; connecting flows are not established. Components and totals may overlap.
Segment
Separate filed amounts; connecting flows are not established. Components and totals may overlap.
Finer product or service dollar figures and nonoverlapping groupings are shown only where supported by the retained filing evidence. Growth percentages are never converted to revenue dollars.
Historical revenue and expense breakdown
Revenue and expense 3 month
| Period end | Revenue | Revenue including tax | Cost of revenue | Research and development | Selling, general and administrative | Operating expenses | Income tax | Net income |
|---|---|---|---|---|---|---|---|---|
| 2026-06-30 | $1.37B | (m) | $570.00M | $92.00M | $449.00M | (m) | $2.00M | $54.00M |
| 2026-03-31 | $1.37B | (m) | $586.00M | $97.00M | $381.00M | (m) | $30.00M | $57.00M |
| 2025-12-31 | $1.14B* | (m) | $555.00M* | $93.00M* | $338.00M* | (m) | $17.00M* | -$276.00M* |
| 2025-09-30 | $1.14B | (m) | $530.00M | $89.00M | $351.00M | (m) | -$16.00M | -$34.00M |
| 2025-06-30 | $1.24B | (m) | $528.00M | $92.00M | $400.00M | (m) | $14.00M | $11.00M |
| 2025-03-31 | $1.19B | (m) | $509.00M | $94.00M | $341.00M | (m) | -$7.00M | $67.00M |
| 2024-09-30 | $1.03B | (m) | $492.00M | $87.00M | $323.00M | (m) | $195.00M | $364.00M |
| 2024-06-30 | $1.18B | (m) | $495.00M | $89.00M | $354.00M | (m) | $18.00M | -$50.00M |
| 2024-03-31 | $1.21B | (m) | $515.00M | $87.00M | $337.00M | (m) | -$20.00M | $32.00M |
| 2023-09-30 | $1.07B | (m) | $487.00M | $86.00M | $313.00M | (m) | -$1.00M | -$1.10B |
| 2023-06-30 | $1.06B | (m) | $434.00M | $81.00M | $353.00M | (m) | $18.00M | -$97.00M |
| 2023-03-31 | $1.26B | (m) | $494.00M | $81.00M | $327.00M | (m) | $5.00M | $103.00M |
| 2022-09-30 | $1.03B | $1.03B | $472.00M | $78.00M | $298.00M | (m) | $21.00M | -$65.00M |
| 2022-06-30 | $1.18B | $1.18B | $484.00M | $82.00M | $343.00M | (m) | -$4.00M | -$10.00M |
| 2022-03-31 | $1.23B | $1.23B | $509.00M | $81.00M | $323.00M | (m) | $24.00M | $51.00M |
| 2021-12-31 | (m) | $1.11B | (m) | (m) | $327.00M | (m) | -$15.00M | -$105.00M |
| 2021-09-30 | $1.13B | $1.13B | $502.00M | $94.00M | $342.00M | (m) | -$22.00M | -$108.00M |
| 2021-06-30 | $1.28B | $1.28B | $551.00M | $94.00M | $385.00M | (m) | -$37.00M | -$206.00M |
| 2021-03-31 | $1.24B | $1.24B | $566.00M | $89.00M | $349.00M | (m) | -$13.00M | -$64.00M |
| 2020-12-31 | (m) | $1.14B | $596.20M | (m) | (m) | $486.80M | $4.70M | -$322.80M |
| 2020-09-30 | $890.00M | (m) | $442.00M | $88.00M | $278.00M | (m) | -$74.00M | -$135.00M |
| 2020-06-30 | $586.00M | (m) | $296.00M | $59.00M | $163.00M | (m) | -$24.00M | -$53.00M |
| 2020-03-31 | $658.00M | (m) | $333.00M | $67.00M | $182.00M | (m) | -$19.00M | -$49.00M |
| 2019-12-31 | (m) | $787.00M | $410.10M | (m) | (m) | $253.20M | $5.20M | -$9.50M |
| 2019-09-30 | $771.30M | $771.30M | $360.40M | $69.90M | $192.30M | $262.20M | -$22.50M | $10.00M |
| 2019-06-30 | $781.60M | $781.60M | $356.00M | $68.80M | $200.90M | $269.70M | $14.30M | $35.90M |
| 2019-03-31 | $731.10M | $731.10M | $343.80M | $64.10M | $181.10M | $245.20M | $13.30M | $31.50M |
| 2018-12-31 | (m) | $799.30M | $412.50M | (m) | (m) | $246.20M | -$18.60M | $16.40M |
| 2018-09-30 | $761.10M | $761.10M | $369.80M | $58.90M | $179.00M | $237.90M | $18.60M | $60.20M |
| 2018-06-30 | $770.20M | $770.20M | $431.50M | $61.40M | $191.10M | $252.50M | $22.80M | -$62.80M |
| 2018-03-31 | $736.20M | $736.20M | $360.00M | $65.20M | $180.00M | $245.20M | $4.80M | $72.70M |
| 2017-12-31 | (m) | $754.30M | $405.00M | (m) | (m) | $258.80M | $6.10M | -$161.50M |
| 2017-09-30 | $697.10M | $697.10M | $376.20M | $61.90M | $194.70M | $256.60M | $11.60M | -$20.70M |
| 2017-06-30 | (m) | $732.80M | $374.00M | (m) | (m) | $257.80M | $15.00M | -$30.20M |
| 2017-03-31 | (m) | $704.80M | $338.60M | (m) | (m) | $258.30M | $45.40M | -$98.30M |
Revenue and expense 6 month
| Period end | Revenue | Cost of revenue | Research and development | Selling, general and administrative | Income tax | Net income |
|---|---|---|---|---|---|---|
| 2026-06-30 | $2.74B | $1.16B | $189.00M | $830.00M | $32.00M | $111.00M |
| 2025-06-30 | $2.43B | $1.04B | $186.00M | $741.00M | $7.00M | $78.00M |
| 2024-06-30 | $2.39B | $1.01B | $176.00M | $691.00M | -$2.00M | -$18.00M |
| 2023-06-30 | $2.31B | $928.00M | $162.00M | $680.00M | $23.00M | $6.00M |
| 2022-06-30 | $2.40B | $993.00M | $163.00M | $666.00M | $20.00M | $41.00M |
| 2021-06-30 | $2.52B | $1.12B | $183.00M | $733.00M | -$45.00M | -$271.00M |
| 2020-06-30 | $1.24B | $629.00M | $126.00M | $345.00M | -$43.00M | -$102.00M |
| 2019-06-30 | $1.51B | $699.80M | $132.90M | $382.00M | $27.60M | $67.40M |
| 2018-06-30 | $1.51B | $791.50M | $126.60M | $371.10M | $27.60M | $9.90M |
Revenue and expense 9 month
| Period end | Revenue | Revenue including tax | Cost of revenue | Research and development | Selling, general and administrative | Income tax | Net income |
|---|---|---|---|---|---|---|---|
| 2025-09-30 | $3.57B | (m) | $1.57B | $275.00M | $1.09B | -$9.00M | $44.00M |
| 2024-09-30 | $3.42B | (m) | $1.50B | $263.00M | $1.01B | $193.00M | $346.00M |
| 2023-09-30 | $3.38B | (m) | $1.42B | $248.00M | $993.00M | $22.00M | -$1.09B |
| 2022-09-30 | $3.43B | (m) | $1.47B | $241.00M | $963.00M | $41.00M | -$24.00M |
| 2021-09-30 | $3.65B | (m) | $1.62B | $277.00M | $1.07B | -$71.00M | -$378.00M |
| 2020-09-30 | $2.13B | (m) | $1.07B | $214.00M | $623.00M | -$117.00M | -$237.00M |
| 2019-09-30 | $2.28B | (m) | $1.06B | $202.80M | $574.30M | $5.10M | $77.40M |
| 2018-09-30 | $2.27B | $2.27B | $1.16B | $185.50M | $550.10M | $46.20M | $70.10M |
| 2017-09-30 | $2.13B | $2.13B | $1.09B | $189.70M | $583.00M | $72.00M | -$149.20M |
Revenue and expense 12 month
| Period end | Revenue | Revenue including tax | Cost of revenue | Research and development | Selling, general and administrative | Income tax | Net income |
|---|---|---|---|---|---|---|---|
| 2025-12-31 | $4.71B | (m) | $2.12B | $368.00M | $1.43B | $8.00M | -$232.00M |
| 2024-12-31 | $4.44B | (m) | $2.00B | $344.00M | $1.31B | $150.00M | $338.00M |
| 2023-12-31 | $4.42B | (m) | $1.93B | $327.00M | $1.28B | $36.00M | -$1.23B |
| 2022-12-31 | $4.41B | $4.41B | $1.91B | $321.00M | $1.26B | $6.00M | -$78.00M |
| 2021-12-31 | $4.76B | $4.76B | $2.13B | $369.00M | $1.40B | -$88.00M | -$483.00M |
| 2020-12-31 | $3.27B | $3.27B | $1.67B | $329.00M | $997.00M | -$103.00M | -$574.00M |
| 2019-12-31 | $3.07B | $3.07B | $1.47B | $270.00M | $760.00M | $10.00M | $68.00M |
| 2018-12-31 | $3.07B | $3.07B | $1.57B | $246.60M | $735.20M | $27.60M | $86.50M |
| 2017-12-31 | $2.89B | $2.89B | $1.49B | $251.70M | $779.80M | $78.10M | -$310.70M |
| 2016-12-31 | $2.91B | $2.91B | $1.41B | $265.80M | $784.80M | $25.50M | -$47.90M |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| MADRIGAL PHARMACEUTICALS, INC. (MDGL) | United States | $11.859B | -38.17 |
| BIOMARIN PHARMACEUTICAL INC (BMRN) | United States | $11.879B | 151.80 |
| Axsome Therapeutics, Inc. (AXSM) | United States | $10.274B | -66.82 |
| CORCEPT THERAPEUTICS INC (CORT) | United States | $12.804B | 169.10 |
| BridgeBio Pharma, Inc. (BBIO) | United States | $12.947B | -20.72 |
| ARROWHEAD PHARMACEUTICALS, INC. (ARWR) | United States | $9.331B | -42.28 |
| Summit Therapeutics Inc. (SMMT) | United States | $13.071B | -13.21 |
| CYTOKINETICS INC (CYTK) | United States | $9.130B | -11.86 |
| Protagonist Therapeutics, Inc (PTGX) | United States | $8.883B | 95.52 |
| TG THERAPEUTICS, INC. (TGTX) | United States | $8.805B | 19.05 |